196 related articles for article (PubMed ID: 12385035)
21. Identification of tubulin as the molecular target of proapoptotic pyrrolo-1,5-benzoxazepines.
Mulligan JM; Greene LM; Cloonan S; Mc Gee MM; Onnis V; Campiani G; Fattorusso C; Lawler M; Williams DC; Zisterer DM
Mol Pharmacol; 2006 Jul; 70(1):60-70. PubMed ID: 16571652
[TBL] [Abstract][Full Text] [Related]
22. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules.
Bai R; Friedman SJ; Pettit GR; Hamel E
Biochem Pharmacol; 1992 Jun; 43(12):2637-45. PubMed ID: 1632820
[TBL] [Abstract][Full Text] [Related]
23. Concerning the chemical nature of tubulin subunits that cap and stabilize microtubules.
Caplow M; Fee L
Biochemistry; 2003 Feb; 42(7):2122-6. PubMed ID: 12590601
[TBL] [Abstract][Full Text] [Related]
24. In vitro effect of cryptophycin 52 on microtubule assembly and tubulin: molecular modeling of the mechanism of action of a new antimitotic drug.
Barbier P; Gregoire C; Devred F; Sarrazin M; Peyrot V
Biochemistry; 2001 Nov; 40(45):13510-9. PubMed ID: 11695898
[TBL] [Abstract][Full Text] [Related]
25. Derivatives of 5,6-diphenylpyridazin-3-one: synthetic antimitotic agents which interact with plant and mammalian tubulin at a new drug-binding site.
Batra JK; Powers LJ; Hess FD; Hamel E
Cancer Res; 1986 Apr; 46(4 Pt 2):1889-93. PubMed ID: 3948171
[TBL] [Abstract][Full Text] [Related]
26. Identification of MINUS, a small polypeptide that functions as a microtubule nucleation suppressor.
Fanara P; Oback B; Ashman K; Podtelejnikov A; Brandt R
EMBO J; 1999 Feb; 18(3):565-77. PubMed ID: 9927416
[TBL] [Abstract][Full Text] [Related]
27. Kinetic stabilization of microtubule dynamics by estramustine is associated with tubulin acetylation, spindle abnormalities, and mitotic arrest.
Mohan R; Panda D
Cancer Res; 2008 Aug; 68(15):6181-9. PubMed ID: 18676841
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin.
Hamel E
Cell Biochem Biophys; 2003; 38(1):1-22. PubMed ID: 12663938
[TBL] [Abstract][Full Text] [Related]
29. Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity.
Buey RM; Barasoain I; Jackson E; Meyer A; Giannakakou P; Paterson I; Mooberry S; Andreu JM; Díaz JF
Chem Biol; 2005 Dec; 12(12):1269-79. PubMed ID: 16356844
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, and biological evaluation of thiophene analogues of chalcones.
Romagnoli R; Baraldi PG; Carrion MD; Cara CL; Cruz-Lopez O; Preti D; Tolomeo M; Grimaudo S; Di Cristina A; Zonta N; Balzarini J; Brancale A; Sarkar T; Hamel E
Bioorg Med Chem; 2008 May; 16(10):5367-76. PubMed ID: 18440234
[TBL] [Abstract][Full Text] [Related]
31. N-terminal stathmin-like peptides bind tubulin and impede microtubule assembly.
Clément MJ; Jourdain I; Lachkar S; Savarin P; Gigant B; Knossow M; Toma F; Sobel A; Curmi PA
Biochemistry; 2005 Nov; 44(44):14616-25. PubMed ID: 16262261
[TBL] [Abstract][Full Text] [Related]
32. Gamma-tubulin nucleation: template or protofilament?
Erickson HP
Nat Cell Biol; 2000 Jun; 2(6):E93-6. PubMed ID: 10854332
[TBL] [Abstract][Full Text] [Related]
33. The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristine-like properties.
Beyer CF; Zhang N; Hernandez R; Vitale D; Nguyen T; Ayral-Kaloustian S; Gibbons JJ
Cancer Chemother Pharmacol; 2009 Sep; 64(4):681-9. PubMed ID: 19132373
[TBL] [Abstract][Full Text] [Related]
34. Microtubule-targeted anticancer agents and apoptosis.
Bhalla KN
Oncogene; 2003 Dec; 22(56):9075-86. PubMed ID: 14663486
[TBL] [Abstract][Full Text] [Related]
35. Indole, a core nucleus for potent inhibitors of tubulin polymerization.
Brancale A; Silvestri R
Med Res Rev; 2007 Mar; 27(2):209-38. PubMed ID: 16788980
[TBL] [Abstract][Full Text] [Related]
36. Ceratamines, structurally simple microtubule-stabilizing antimitotic agents with unusual cellular effects.
Karjala G; Chan Q; Manzo E; Andersen RJ; Roberge M
Cancer Res; 2005 Apr; 65(8):3040-3. PubMed ID: 15833830
[TBL] [Abstract][Full Text] [Related]
37. Mechanism of action cryptophycin. Interaction with the Vinca alkaloid domain of tubulin.
Smith CD; Zhang X
J Biol Chem; 1996 Mar; 271(11):6192-8. PubMed ID: 8626409
[TBL] [Abstract][Full Text] [Related]
38. Indicine N-oxide binds to tubulin at a distinct site and inhibits the assembly of microtubules: a mechanism for its cytotoxic activity.
Appadurai P; Rathinasamy K
Toxicol Lett; 2014 Feb; 225(1):66-77. PubMed ID: 24300171
[TBL] [Abstract][Full Text] [Related]
39. Physiochemical aspects of tubulin-interacting antimitotic drugs.
Correia JJ; Lobert S
Curr Pharm Des; 2001 Sep; 7(13):1213-28. PubMed ID: 11472263
[TBL] [Abstract][Full Text] [Related]
40. Anticancer therapy with novel tubulin-interacting drugs.
Kavallaris M; Verrills NM; Hill BT
Drug Resist Updat; 2001 Dec; 4(6):392-401. PubMed ID: 12030786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
